MedTrace Logo

MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments

NCT04762043 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication for those with vocal impairments that resulted from surgical treatment of laryngeal and oropharyngeal cancers.

Conditions

  • Rehabilitation of Speech and Language Disorders
  • Speech Disorders
  • Speech, Alaryngeal
  • Communication Aids for Disabled
  • Speech Perception
  • Speech Intelligibility

Interventions

DEVICE

Experimental System: MyoVoice

Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.

DEVICE

Reference System: Electrolarynx

Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.

Sponsors & Collaborators

  • Altec Inc.

    lead INDUSTRY

Principal Investigators

  • Gianluca DeLuca · Altec Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-12
Primary Completion
2023-11-08
Completion
2023-11-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762043 on ClinicalTrials.gov